Cancer is a generic term for a large group of diseases that are caused by the transformation of normal cells into malignant tumor cells. Despite the great successes have been achieved in cancer research and treatment in the last decades, cancer remains a great challenge for humanity and causes great suffering to the physical and mental health of patients. Nowadays, cancer has become the second leading cause of death worldwide. Cancer cells have many significantly different biological characteristics and exhibit unlimited proliferative potential. Therefore, drugs with anticancer activity are one of the hot spots of clinical research, and the search for novel chemotherapeutic treatments for cancer is one of the most challenging tasks in modern pharmacology.
BOC Sciences’ anticancer screening compound library contains more than 6,300 novel drug-like screening compounds with potential anti-tumor activity that enable to target against various cancer types such as prostate and breast cancers, leukemia, lymphoma, and carcinoma. It is designed as a useful tool for high-throughput screening (HTS) in anticancer drug discovery studies.
Figure 1. High-throughput screening of cancer drugs to identify which drugs should be used for radiosensitisation in the context of single gene mutations in colorectal cancer. (Rebecca, C.; et al. 2019)
Application
- Study of oncology mechanism
- Anti-tumor drug screening
- Drug structure optimization
- Discovery of new drug targets
Library Design
Anticancer Focused Compound Library via 2D Fingerprint Similarity Search
a. Firstly, a 2D fingerprint similarity search is performed against the BOC Sciences HTS compound collection
b. Nearly 1,500 structurally diverse compounds with potential inhibitory activity against the following cancer cell lines for cell-based phenotypic screening projects are delivered:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
c. Then, the 80% similarity cut-off (Tanimoto) is conducted to filter the HTS compound collection for analogs of molecules with known activity against different cancer-related targets
d. Finally, around 4,800 potential anti-cancer compounds are selected successfully for the following targets:
- Anoctamin-1
- Lysine-specific demethylase 5B
- ATP-binding cassette sub-family G member 2
- MAP kinase p38 alpha
- Beta-hexosaminidase subunit beta
- Mitogen-activated protein kinase kinase kinase 8
- Breast cancer type 1 susceptibility protein
- Mixed lineage kinase 7
- Bromodomain testis-specific protein
- Nuclear receptor coactivator 3
- Cyclin-dependent kinase 2-associated protein 1
- PDZ-binding kinase
- L-type amino acid transporter 3
- Serine/threonine-protein kinase WNK2
Anticancer Screening Compound Library Characteristics
- No PAINS or toxic substances/unwanted functions: filtered by strict ‘Ro5-like’ physicochemical and most stringent in-house structural filters
- Confirmed bioactivity and safety by preclinical studies and clinical trials
- Targets involved PI3K, HDAC, mTOR, CDK, JAK and other cancer-related targets
- Structural diversity, significant efficacy, and cellular penetration
- Structural document, IC50, and other chemical and biological data are provided
- Tanimoto index ≥ 0.8
- All compounds are continually updated
- Compound cherry-picking service is provided
What We Deliver
- Delivered within 2 weeks in any customer-preferred format
- Powders, dry films or DMSO solutions formatted in vials, 96 or 384-well plates
- All compounds have a minimum purity of 90% assessed by 1H NMR and HPLC
- Analytical data is provided
BOC Sciences provides professional, rapid and high-quality services of Anticancer Screening Compound Library design at competitive prices for global customers. Personalized and customized services of Anticancer Screening Compound Library design can satisfy any innovative scientific study demands. Our clients have direct access to our staff and prompt feedback to their inquiries. If you are interested in our services, please contact us immediately!
Reference
- Rebecca, C.; et al. Identification of anticancer drugs to radiosensitise BRAF -wild-type and mutant colorectal cancer. Cancer Biology and Medicine. 2019. 16(2): 234-246.
